Cost-Effectiveness Analysis of Apixaban Versus Rivaroxaban for Prevention of Stroke in Patients with Non-Valvular Atrial Fibrillation in Spain
Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.1268
https://www.valueinhealthjournal.com/article/S1098-3015(13)03173-2/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1116
First Page :
A523
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03173-2&doi=10.1016/j.jval.2013.08.1268